I assume there's also hurdles for generic manufacturers if all the combination Zan+Decitabine trials (approvals) were actually Zan+Inqovi trials?
It's a good question, @KingBuzzo. If I were Astex, I'd be looking for some of the upside in Zan to offset the inqovi portfolio risk.
Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-81
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.045(2.84%) |
Mkt cap ! $276.1M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.65 | $1.57 | $69.13K | 42.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13340 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 974 | 1 |
View Market Depth
| Last trade - 15.05pm 06/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |